Nile Therapeutics, Inc.

Nile Therapeutics is a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular disease and other areas of unmet medical need.

Cenderitide is a novel rationally designed chimeric natriuretic peptide in clinical studies for an initial indication of acute decompensated heart failure. » More

Upcoming Events

Presentation of clinical data at the American College of Cardiology (ACC) 61th Scientific Session » More

» Download Poster

May 15, 2012 - Nile Therapeutics Reports 2012 First Quarter Financial Results » Read

April 4, 2012 - Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering » Read

March 30, 2012 - Nile Therapeutics, Inc. To Raise $1.4 Million in Registered Direct Offering » Read

Interested investors or potential investors may conveniently receive E-mail alert messages whenever certain new company information is posted to this site. To automatically receive Nile Therapeutics, Inc. e-mail alerts, enter your e-mail address and click on the Subscribe button.